Early trials of the EndoArt artificial endothelial implant, including Heidelberg’s 2-year follow-up, show promising safety and efficacy, making it a viable option for treating endothelial dysfunction amid global tissue shortages
Early trials of the EndoArt artificial endothelial implant, including Heidelberg’s 2-year follow-up, show promising safety and efficacy, making it a viable option for treating endothelial dysfunction amid global tissue shortages